Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cardiology Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Andika Sitepu
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Resolution of ST-Segment Depression In Reciprocal Leads As Predictor Mayor Adverse Cardiac Event For ST-Segment Elevation Myocardial Infarction With Fibrinolytic Therapy Aldino Satria Adhitya; Andika Sitepu; Zulfikri Mukhtar; Harris Hasan
Jurnal Kardiologi Indonesia Vol 39 No 2 (2018): Indonesian Journal of Cardiology: April-June 2018
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.v39i2.735

Abstract

Background: ST Elevation Myocardial Infarction (STEMI) may cause Major Cardiovascular Event (MACE). Revascularization needs to be done in all STEMI patients to restore coronary blood flow, hence saving myocardial perfusion. ST Segment Depression (STSD) in reciprocal ECG lead is associated with poor prognosis in STEMI patients receiving fibrinolytic therapy. The main purpose of this study is to evaluate MACE in STEMI patients receiving fibrinolytic therapy using resolution in STSD. Methods: This cohort prospective study with 60 subjects of STEMI patients which are evaluated for MACE (death, heart failure, and rehospitalization) within 30 days after myocardial infarction. Resolution in STSD is defined as resolution ≥ 50% STSD in reciprocal leads within 90 minutes after fibrinolytic therapy.Results: Bivariate analysis showed that Ejection fraction (EF) <40% with OR 8,32 (2,11-32,74), p=0,001; smoking with OR 4,17 (1,05-16,57), p=0,034; Anterior STEMI with OR 3,94 (1,11-13,90), p= 0,027; Creatinine > 1,97 mg/dl with OR 3,69 (1,18-11,55), p= 0,022; complete outpatient medication with OR 5,23 (1,61-17,01), p= 0,004; fragmented QRS with OR 5,23 (1,61-17,01), p= 0,001; resolution in STSD with OR 26,35 (5,16-134, 40), p=<0,001; resolution in ST Segment Elevation with OR 10,5 (2,97-37,24), p=<0,001; are proven to be determining factor for MACE within 30 days. Multivariate analysis showed that among those determining factors for MACE, resolution in STSD on reciprocal leads is evidently the most dominant factor for predicting MACE within 30 days in STEMI patients receiving fibrinolytic therapy [OR 11.47 (1.14-115.10), p=0.038].Conclusion: There is significant difference in MACE within 30 days after myocardial infarction (MI) between patients with and without resolution in STSD. The subjects without resolution in STSD showed higher MACE incidence. Resolution in STSD is evidently an independent predictor for MACE within 30 days after myocardial infarction in STEMI patients.Keywords: Resolution in STSD, MACE, STEMI, Fibrinolytic
Description of Clinical Severity, Laboratory Results, and ECG of COVID-19 Patients Who Received Doses I and II of the COVID-19 Vaccine at Haji Adam Malik General Hospital from April to August 2021 Shafira Pramesi Putri; Andika Sitepu; Yuke Sarastri; Setia Putra Tarigan
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Vol. 4 No. 4 (2022): Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Publisher : TALENTA Publisher, Universitas Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32734/jetromi.v4i4.11000

Abstract

Introduction: COVID-19 patients with comorbidities (hypertension or cardiovascular disease) have a high mortality rate and are at high risk of showing severe symptoms of COVID-19. One of the preventions to avoid COVID-19 is to vaccinate against COVID-19. The COVID-19 vaccine has proven safe and effective in patients with comorbidities because the vaccine can prevent severe symptoms of COVID-19. Aim: To describe the clinical severity, laboratory results, and ECG of COVID-19 patients with cardiovascular comorbidities who received the first and second doses of COVID-19 vaccination at Haji Adam Malik General Hospital from April to August 2021. Methods: A descriptive retrospective study using a cross-sectional study design. Total sampling was used, which fits the inclusion and exclusion criteria. Results: Out of the 71 COVID-19 patients with cardiovascular comorbidities, the majority were found to be male patients (57.7%), aged ≥ 65 years (22.5%), with comorbid hypertension (84.5%), and had received vaccine dose II (97.2%). Most patients had mild symptoms (47.9%), abnormal ECG results (73.2%), and varied laboratory results. Conclusion: Most patients had received the second COVID-19 vaccine, showing moderate symptoms of COVID-19, abnormal ECG results, and varied laboratory results.
Co-Authors Aldino Satria Adhitya Harris Hasan Setia Putra Tarigan Shafira Pramesi Putri Yuke Sarastri Zulfikri Mukhtar